Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,360 | 172 | 2,173 |
| Samples | 501 | 67 | 429 |
| Peptides | 319 | 42 | 284 |
Function
STAT3 · Signal transducer and activator of transcription 3
The protein encoded by this gene is a member of the STAT protein family. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated through phosphorylation in response to various cytokines and growth factors including IFNs, EGF, IL5, IL6, HGF, LIF and BMP2. This protein mediates the expression of a variety of genes in response to cell stimuli, and thus plays a key role in many cellular processes such as cell growth and apoptosis. The small GTPase Rac1 has been shown to bind and regulate the activity of this protein. PIAS3 protein is a specific inhibitor of this protein. This gene also plays a role in regulating host response to viral and bacterial infections. Mutations in this gene are associated with infantile-onset multisystem autoimmune disease and hyper-immunoglobulin E syndrome. [provided by RefSeq, Aug 2020].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 301 amino-acid changes on canonical ENST00000264657 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in STAT3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in STAT3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 108/2534 4% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 16/612 3% |
| Hodgkins Lymphoma | 2/16 12% | 2/122 2% |
| Melanoma | 5/210 2% | 40/1899 2% |
| Ovarian Carcinoma | 6/109 6% | 13/998 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 13/752 2% |
| Gastric Carcinoma | 3/74 4% | 21/1809 1% |
| Bladder Carcinoma | 0/58 0% | 12/956 1% |
| Plasma Cell Myeloma | 2/44 5% | 2/305 1% |
| Head and Neck Carcinoma | 0/85 0% | 18/1574 1% |
| Colorectal Carcinoma | 9/143 6% | 27/3239 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 11/1390 1% |
| Prostate Carcinoma | 1/13 8% | 18/2105 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Hepatocellular Carcinoma | 0/46 0% | 19/2210 1% |
| Breast Carcinoma | 4/144 3% | 20/3264 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Other Solid Cancers | 0/94 0% | 11/1515 1% |
| Non-Cancerous | 0/104 0% | 6/830 1% |
| Esophageal Carcinoma | 2/23 9% | 3/769 0% |
| Biliary Tract Carcinoma | 1/54 2% | 5/950 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 9/1592 1% |
| Other Blood Cancers | 2/61 3% | 13/2725 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 13/2550 1% |
| Pancreatic Carcinoma | 1/89 1% | 5/1611 0% |
Mutation Distribution
Where STAT3 is mutated · all tissues, split by cell line vs tissue
How many mutations in STAT3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,360 mutations in STAT3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|